These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 29452772)

  • 1. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of GPNMB in renal eosinophilic tumors and its value in differential diagnosis].
    Wang Y; Hou MY; Fu Y; Meng K; Wu HY; Chen J; Xu YM; Shi J; Fan XS
    Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):358-363. PubMed ID: 36973196
    [No Abstract]   [Full Text] [Related]  

  • 3. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
    Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
    BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney-specific cadherin correlates with the ontogenetic origin of renal cell carcinoma subtypes: an indicator of a malignant potential?
    Horstmann M; Geiger LM; Vogel U; Schmid H; Hennenlotter J; Kuehs U; Merseburger AS; Kruck S; Stenzl A; Bedke J
    World J Urol; 2012 Aug; 30(4):525-31. PubMed ID: 21928123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
    Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
    Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel biomarkers to distinguish clear cell and non-clear cell renal cell carcinoma using bioinformatics and machine learning.
    Panwoon C; Seubwai W; Thanee M; Sangkhamanon S
    PLoS One; 2024; 19(6):e0305252. PubMed ID: 38857246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
    Linehan WM; Ricketts CJ
    Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications.
    Kruck S; Hennenlotter J; Vogel U; Schilling D; Gakis G; Hevler J; Kuehs U; Stenzl A; Schwentner C
    BJU Int; 2012 Feb; 109(4):634-8. PubMed ID: 21711439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
    Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
    Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms.
    Skala SL; Wang X; Zhang Y; Mannan R; Wang L; Narayanan SP; Vats P; Su F; Chen J; Cao X; Siddiqui J; Argani P; Cieślik MP; Giordano TJ; Chinnaiyan AM; Dhanasekaran SM; Mehra R
    Eur Urol; 2020 Jul; 78(1):63-74. PubMed ID: 32299640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of CT, MRI imaging features of renal cell carcinoma with different histopathological types.
    Wang X; Kong W; Wang Y; Wang Y; Chen Y; Shi Z; Liu Y
    J BUON; 2021; 26(5):2053-2058. PubMed ID: 34761616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
    Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
    BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
    Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
    Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis.
    Avulova S; Cheville JC; Lohse CM; Gupta S; Potretzke TA; Tsivian M; Thompson RH; Boorjian SA; Leibovich BC; Potretzke AM
    Eur Urol; 2021 Feb; 79(2):225-231. PubMed ID: 33172723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.
    Wu P; Liu JL; Pei SM; Wu CP; Yang K; Wang SP; Wu S
    BMC Cancer; 2018 Mar; 18(1):287. PubMed ID: 29534679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
    Zhao H; Leppert JT; Peehl DM
    PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation of microvascular density and clinicopathological factors in different subtypes of renal cell carcinoma].
    Zhang YH; Yang Q; Cui W; Liu YX; Liu SX; Yao X
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):117-22. PubMed ID: 20403242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.